文献速递胸部介入CT

手术切除与CT引导经皮消融治疗Ⅰ期非小细胞肺癌的生存结局:系统综述与Meta分析

Survival outcomes for surgical resection versus CT-guided percutaneous ablation for stage I non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2021-01-15

该系统综述与Meta分析比较Ⅰ期非小细胞肺癌手术切除与CT引导经皮消融的生存结局,共纳入8项研究792例患者(手术460例、消融332例)。手术与消融的1~5年总生存率及癌症特异性生存率无显著差异;手术1年和2年无病生存率显著优于消融(OR 2.22,95%CI 1.14-4.34;OR 2.60,95%CI 1.21-5.57),但3~5年无病生存率无显著差异。亚组分析显示亚肺叶切除1年和2年总生存率显著优于射频消融,而肺叶切除与微波消融无显著差异。作者认为手术切除仍是Ⅰ期非小细胞肺癌的最佳选择,但对于不能手术的ⅠA期患者,消融提供了有前景的无病生存、癌症特异性生存和总生存。

要点

  • 手术与消融的1~5年总生存率及癌症特异性生存率无显著差异。
  • 手术1年和2年无病生存率显著优于消融(OR 2.22和2.60)。
  • 亚肺叶切除1年和2年总生存率显著优于射频消融,肺叶切除与微波消融无显著差异。

诊断标准与关键数值

  • 手术与消融的1~5年总生存率及癌症特异性生存率无显著差异。
  • 手术1年无病生存率显著优于消融(OR 2.22,95%CI 1.14-4.34)。
  • 手术2年无病生存率显著优于消融(OR 2.60,95%CI 1.21-5.57)。
  • 手术与消融的3~5年无病生存率无显著差异。
  • 亚组分析:亚肺叶切除(楔形切除或肺段切除)1年总生存率显著优于射频消融(OR 2.85,95%CI 1.33-6.10),2年总生存率显著优于射频消融(OR 4.54,95%CI 2.51-8.21);肺叶切除与微波消融的总生存率无显著差异。

临床应用与阅片要点

  • 对于可手术的Ⅰ期非小细胞肺癌患者,手术切除仍是首选。
  • 对于不能手术的ⅠA期非小细胞肺癌患者,CT引导微波或射频消融可能是有前景的替代方案。
  • 作者认为未来需要前瞻性随机对照试验进一步验证。

局限性

  • 纳入研究间结果存在异质性。
  • 作者指出需要未来前瞻性随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Multiple cohort studies have compared surgical resection with CT-guided percutaneous ablation for patients with stage 1 non-small cell lung cancer (NSCLC); however, the results have been heterogeneous. This systematic review and meta-analysis aims to compare surgery with ablation for stage 1 NSCLC.

METHOD: A search of five databases was performed from inception to 5 July 2020. Studies were included if overall survival (OS), cancer-specific survival (CSS), and/or disease-free survival (DFS) were compared between patients treated with surgical resection versus ablation (radiofrequency ablation (RFA) or microwave ablation (MWA)) for stage 1 NSCLC. Pooled odds ratios (OR) were calculated.

RESULTS: A total of eight studies were included (total 792 patients: 460 resection and 332 ablation). There were no significant differences in 1- to 5-year OS or CSS between surgery versus ablation. There were significantly better 1- and 2-year DFS for surgery over ablation (OR 2.22, 95% CI 1.14-4.34; OR 2.60, 95% CI 1.21-5.57 respectively), but not 3- to 5-year DFS. Subgroup analysis demonstrated no significant OS difference between lobectomy and MWA, but there were significantly better 1- and 2-year OS with sublobar resection (wedge resection or segmentectomy) versus RFA (OR 2.85, 95% CI 1.33-6.10; OR 4.54, 95% CI 2.51-8.21, respectively). In the two studies which only included patients with stage 1A NSCLC, pooled outcomes demonstrated no significant differences in 1- to 3-year OS or DFS between surgery versus ablation.

CONCLUSION: Surgical resection of stage 1 NSCLC remains the optimal choice. However, for non-surgical patients with stage 1A, ablation offers promising DFS, CSS, and OS. Future prospective randomized controlled trials are warranted.

KEY POINTS: • Surgical resection of stage 1 NSCLC remains the optimal choice. • In patients with stage 1A NSCLC who are not surgical candidates, CT-guided microwave or radiofrequency ablation may be an alternative which offers promising disease-free survival and overall survival.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chan MV, Huo YR, Cao C, et al. Survival outcomes for surgical resection versus CT-guided percutaneous ablation for stage I non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Eur Radiol. 2021. PMID: 33449192. doi:10.1007/s00330-020-07634-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。